Syntropy Announces Collaboration with Evidium to Advance Data-Centric Healthcare
Today, Syntropy, a partnership between Merck and Palantir Technologies Inc., announced a collaboration with Evidium, a developer of a healthcare platform that enables AI use in a responsible, reliable, and referenceable manner. The organizations will make end-to-end medical knowledge more computational and improve data quality for clinical research and practice. The coalition will be facilitated through Syntropy’s secure data collaboration platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927301328/en/
Evidium’s Referenced AI platform will play a key role in transforming narrative-form information into AI-ready knowledge at the elemental level. This will allow clinical data to be disseminated and utilized with unprecedented scale and precision. Syntropy’s secure, collaborative ecosystem will enable researchers to review high-quality data, share insights, and apply their findings to clinical trials, helping to generate more specific treatment options. The healthcare industry will also benefit from Evidium’s methods that responsibly use AI and Syntropy’s ethical data practices.
"Evidium's vision and platform aligns directly with our mission of making science faster," said James Kugler, Director of Syntropy. "Together, Syntropy and Evidium will work to make clinical research computable and scalable by simplifying the process of entering quality medical data onto a secure, trustworthy platform. The joint efficiencies will break down the silos that have hampered research to support collaboration on data. This will help shorten the time it takes to uncover crucial insights and deploy lifesaving discoveries."
Introducing an AI Operating System for Healthcare
The coalition comes at a time where, despite an overabundance of clinical data and evidence, much of it is not high-quality enough to provide actionable insights to spur new research knowledge. Additionally, manually extracting, reviewing, comparing, and translating medical evidence takes a tremendous amount of time and is highly costly. Combining Evidium’s Referenced AI capabilities with Syntropy’s secure data curation and collaboration environment will address these inconsistencies by improving data quality and the speed at which valuable information is extracted.
Providing the critical pieces of an AI Operating System (OS), the two platforms will reshape the complex relationships between data, knowledge, and evidence to convert the insights into AI-ready, scalable intelligence. This will allow researchers to sidestep traditional barriers to develop better clinical expertise while establishing a solid foundation through links to evidence and clinical guidelines. The two organizations will aim to create a self-perpetuating cycle of refined data and knowledge where precision medicine is accelerated for every patient.
Combining Trustworthy Data with Responsible, Reliable AI
The combination of the two platforms will enable more reliable, lower bias and more precise usage of Generative AI across use cases, both in workflow and analytics from vast and complex sources. While powerful, Large Language Models (LLMs) and vector databases alone do not provide the precision or timeliness that are essential factors in healthcare. By grounding LLMs in data that the two organizations have curated, modeled, and made computational, users can be ensured that AI is aligned and anchored in customer-customizable, high-quality data at the elemental level.
Syntropy enables researchers, healthcare institutions, and other healthcare stakeholders to contribute, share, view, and collaborate on data in a secure, unified platform. Founded on three key elements – traceability, contextualization, and governance – Syntropy ensures the source of the data is always available, ownership is protected, and all changes to the data can be tracked, so data remains trustworthy. Syntropy empowers healthcare providers, researchers, and collaborators to derive insights from every data point they collect and generate insights in a secure, compliant, and ethical manner.
"We are excited to announce this collaborative effort with Syntropy. Our teams are aligned to enable our customers to maximize the impact of their medical knowledge and bring trustworthy AI benefits to patients and every expert across the system,” said Carl Bate, Founder and CEO of Evidium. "There is too much at stake not to get this right. Our customers need AI systems to be expert-controlled and not let AI get out of control. We will achieve this by grounding AI in elemental, scientific quality data and referenceable knowledge. Syntropy plus Evidium enables this vision for our customers.”
Eventually, the offering will be expanded to more healthcare and biopharmaceutical organizations, with the goal of positively impacting patient quality and experience.
Syntropy Technologies LLC is a technology company specializing in healthcare data governance, harmonization, and collaboration solutions aimed at unlocking the value of real-world data. Syntropy empowers healthcare providers, researchers, and collaborators to derive insights from every point of data they collect and generate in a secure, compliant, and ethical manner. Syntropy is a partnership between Merck (DAX: MKGAF), and Palantir Technologies Inc. (NYSE: PLTR). Foundry is a licensed trademark of Palantir. Syntropy is headquartered in Cambridge, MA. Follow us on LinkedIn and Twitter.
Evidium, Inc. is a healthcare AI and computational evidence company providing solutions to maximize the impact of medical knowledge across clinical practice and research, and leverage the power of AI responsibly, reliably and with referenceability. Through its first-of-its-kind combination of Referenced AI with Generative AI, Evidium converts medical knowledge into reliable AI solutions for enterprises. These solutions encompass: Clinical Copilot for next-best-action assistance in workflow; Fusion, for AI Evidence Engineering and Distribution, and Nova LLM for knowledge-based analytics. Headquartered in San Francisco, Evidium is backed by healthcare AI investors including Health2047, a venture studio powered by the American Medical Association and ROBO Global Ventures.
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.
About Palantir Technologies Inc.
Foundational software of tomorrow. Delivered today. Additional information is available at www.palantir.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir's expectations regarding the expected benefits of Palantir's software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events.
These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond Palantir's control. These risks and uncertainties include the ability to meet the unique needs of customers; the failure of Palantir's platforms to satisfy customers or perform as desired; the frequency or severity of any software and implementation errors; Palantir's platforms’ reliability; and customers' ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings Palantir makes with the Securities and Exchange Commission from time to time. Except as required by law, Palantir does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media Contact for Merck and Syntropy:
Director of Marketing
Media Contact for Evidium:
Senior Director, Marketing & Growth Programs, Health2047
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Holdings advises ServiceNow Elite Partner Unifii on its strategic sale to Bain Capital backed Inetum6.12.2023 19:55:00 CET | Press release
Technology Holdings, a global investment bank with offices in North America, Europe and the Asia-Pacific is pleased to announce that it has acted as the exclusive financial advisor to London headquartered Elite ServiceNow partner, Unifii on its strategic sale to Bain Capital backed Inetum, which is headquartered in France. Unifii is the largest independent Elite ServiceNow partner in the United Kingdom and Ireland, and is recognized for its unparalleled expertise in supporting clients through their digital transformation journeys. Unifii enables its clients to achieve successful business outcomes through optimized business workflows. Unifii has a recognized customer ecosystem in multiple sectors, including finance, technology, and the public sector. Its team of certified experts and experienced consultants brings undeniable value to its clients’ national and international projects. With the acquisition of Unifii, Inetum becomes a leading European partner for ServiceNow with nearly 500
Edgio’s Group Vice President of EMEA, Emma Whitmore, to Join the Digital TV Group (DTG) Council6.12.2023 17:00:00 CET | Press release
Edgio, Inc. (Nasdaq: EGIO), the platform of choice for speed, security, and simplicity at the edge, today announced that Emma Whitmore, Group Vice President (GVP) of EMEA, is joining the DTG Council, an important industry steering group, to provide Edgio’s unique perspective and insight on the future of TV distribution. For over 25 years, DTG, the UK's unique, self-funding centre for innovation in digital media technology, has been central to driving digital TV innovation in the UK. The 25-strong member council brings together the best thinkers from across broadcasters, technology providers and manufacturers, including BT, BBC, ITV and Sony, to inform the work, policy and direction of the organisation. Powered by a secure global edge network designed for the unique demands of media, Edgio’s solutions allow companies to operate, monetize and securely deliver video content to millions of global viewers. “Given the wealth of knowledge that Emma brings from more than twenty years in the in
Mavenir CEO Welcomes Recognition of Open RAN Vendor Leadership in ABI Research Ranking6.12.2023 16:19:00 CET | Press release
Pardeep Kohli, CEO of Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has today welcomed the new ranking by global technology intelligence company ABI Research that recognizes Mavenir as the leading vendor in Open Radio Access Network (Open RAN) solutions. In ABI Research’s detailed and independent Competitive Assessment vendor matrix, Mavenir tops all three ranking categories – market leadership, innovation and implementation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206233989/en/ ABI Research Open RAN Vendor Ranking November 2023 (Graphic: Business Wire) Mavenir is classed as the leading innovator in the Open RAN space with an impressive score of 81.5 out of 100, while its achievement of 84.5 out of 100 in the implementation criteria reflects Mavenir’s central role in accelerating Open RAN deployments globally. These key rankings position Ma
Snow Software Announces Winners of the 2023 Partner of the Year Awards6.12.2023 15:00:00 CET | Press release
Snow Software, the global leader in technology intelligence, today announced the winners of the 2023 Partner of the Year Awards. With the launch of the new Snow Partner Program earlier this year, the awards seek to recognize top-performing partners for their work and contributions during a year of change. “It has been an exciting year for partners at Snow, and we wanted to take this opportunity to celebrate our partners and their incredible achievements,” said Vinod Chumber, Vice President, Ecosystem Sales at Snow. “Soaring vendor and cloud prices, ongoing economic uncertainty and the need for investment in new technologies such as artificial intelligence mean that managing technology spend is more critical than ever. The impactful work being done by our partners to deliver Technology Intelligence provides so many opportunities for Snow customers to reduce spend, gain visibility into complex IT environments and prepare for cybersecurity risks.” This year’s Partner of the Year Awards ca
GWI Appoints New Chief Technology Officer, Nick Dearden6.12.2023 15:00:00 CET | Press release
GWI, the global consumer research platform, today announced that it has appointed Nick Dearden as Chief Technology Officer, based in its UK headquarters in London. Nick has over 25 years of experience in technology, with his grassroots as a developer. At GWI he will lead the engineering, IT, and security teams and will be responsible for the company's technology and data management strategy. His role is key to driving forward the company’s agenda to build technology that gives people clarity over their audience in the moment they need it. Nick’s role will focus on the ongoing innovation, scaling, and automation of processes that underpin access to data representative of nearly 3 billion people across 50+ markets. With simplification and ease of access to GWI data a key strategic driver, Nick will be responsible for identifying appropriate technology, such as AI, to define the technology strategy to achieve this. This will enable the company to automate and unlock powerful new features
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom